Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsayil LTE: Long-term spesolimab treatment in hidradenitis suppurativa
2023-508377-82-00Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 34
01
Overview
Phase 3, open-label, single-arm trial of spesolimab in hidradenitis suppurativa (HS), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of treatment emergent adverse events (TEAE). Started Jun 2024; status: completed.
02
Drugs
spesolimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2023-508377-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508377-82-00.